Just a moment, the page is loading...

The effects of maraviroc versus efavirenz in combination with zidovudine/abacavir on the CD4/CD8 ratio in treatment-naïve HIV-infected individuals.








The effects of maraviroc versus efavirenz in combination with zidovudine/abacavir on the CD4/CD8 ratio in treatment-naïve HIV-infected individuals.


Sergio Serrano-Villar, MD PhD


Deparment of Infectious DiseasesUniversity Hospital Ramón y CajalMadrid, Spain.


None


Lead Researcher: None
Researcher 1: SM has received grants and consulting fee from ViiV-Healthcare
Researcher 2: None

Management of Real or Potential Conflicts of Interest
Any potential conflict of interest will be disclosed when data are presented and published.


12 October 2014


A low CD4/CD8 ratio is considered a surrogate marker of immunosenescence and is an independent predictor of all-cause mortality. We have recently described in long-term virally suppressed HIV infected subjects a negative correlation between the CD4/CD8 ratio and inflammation/inmmunosenescence. We also observed that is independently associated with surrogate markers of age-associated disease and non-AIDS-related morbidity and mortality. Collectively, these studies suggest that a low CD4/CD8 ratio despite otherwise effective ART might identify a new clinical phenotype of patients needed of novel interventions. Given the strong clinical implications the impact of different regimens on the CD4/CD8 ratio recovery needs to be analyzed. For this purpose, we herein request the MERIT study, a randomized, double-blind, multicenter phase IIb/III study with an open-label extension phase (240-week follow-up) to assess the efficacy of zidovudine/lamivudine in combination with maraviroc or efavirenz in treatment-naïve patients.



[{ "PostingID": 1406, "Title": "VIIV-A4001026", "Description": "Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine

Medicine: maraviroc, Condition: Infection, Human Immunodeficiency Virus, Phase: 3, Clinical Study ID: A4001026, Sponsor: ViiV" }]

Statistical Analysis Plan


Serrano-Villar S, Caruana G, Zlotnik A, Pérez-Molina JA, Moreno S. Effects of Maraviroc versus Efavirenz in Combination with Zidovudine-Lamivudine on the CD4/CD8 Ratio in Treatment-Naive HIV-Infected Individuals. Antimicrobial Agents and Chemotherapy. 2017; 61(12). doi: 10.1128/AAC.01763-17.PMID: 28993335.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700350/